Medannex’s monoclonal antibody MDX-124 highly active in pancreatic cancer models

Medannex Ltd (Edinburgh) today announced new data for their first-in-class targeted agent, MDX-124, showing significant anti-tumour activity in preclinical pancreatic cancer models. The results were released at the American Society of Clinical Oncology (ASCO) Gastrointestinal Cancer Symposium in San Francisco, USA.

MDX-124 induces cell cycle arrest, preventing cancer cells progressing from the growth phase (G1) to the DNA synthesis phase (S). This causes a significant reduction in cancer cell proliferation and greatly increases primary tumour necrosis. Furthermore, MDX-124 significantly decreases cancer cell migration, and reduces both the incidence and burden of metastatic spread – the major cause of cancer mortality.

In December, Medannex released data showing MDX-124 has potent activity in breast cancer models and significant synergy when combined with widely used chemotherapies cisplatin and paclitaxel. Today’s data demonstrate synergy between MDX-124 and two additional chemotherapies, 5-FU and gemcitabine, which are standard-of-care treatments for several cancers, including pancreatic.

Professor Daniel Palmer, of the University of Liverpool’s Department of Molecular and Clinical Cancer Medicine, commented: ‘Pancreatic cancer is incredibly challenging and we desperately need new therapies. These non-clinical data suggest that MDX-124 could provide a new treatment option as a single agent or in combination with established cancer therapies and clinical trials are now eagerly anticipated.’

Medannex CEO Ian Abercrombie said: ‘We are very encouraged by these data, especially the impressive added benefit when combining MDX-124 with established cancer drugs. This demonstrates great potential for our agent to improve outcomes for patients. We look forward to exploring this further in our imminent First-in-Human study, which will include patients with pancreatic cancer.

The new data were generated by Medannex in collaboration with the University of Liverpool, ARU (Cambridge) and Brighton & Sussex Medical School, and can be viewed in full here


More news and updates

Coulter Partners announces Gerben van 't Klooster as chief development officer at TargED Biopharmaceuticals

Coulter Partners, is pleased to announce the placement of Gerben van 't Klooster as Chief Development Officer (CDO) of TargED Biopharmaceuticals.

Touchlight creates world’s largest DNA manufacturing facilities in London, UK

- Facility will have capacity that exceeds today’s global plasmid DNA demand and can enable commercialisation of genetic medicines. Supplying many of the top biopharmaceutical companies in the world.

Discovery Park and EKC Group join forces to boost STEM careers in Kent

A partnership has been forged between Discovery Park and EKC Group, a further education provider, to inspire more of Kent’s young people to experience a career in science, technology, engineering and maths.

New senior hire for the medical writing team at Boyds

Leading global drug development consultancy Boyds has made a new appointment to its medical writing team in response to rising demand for its services.

More within